Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.（LXRX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · LXRX · 截至 2026年6月9日
活动摘要
买入笔数
8
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Lexicon Pharmaceuticals, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
LXRX 季度内部人买卖趋势
LXRX 内幕交易卖出 · LXRX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · LXRX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
LXRX 高管卖出股份 · LXRX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 3, 2026 | Swain Judith L Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | Sullivan Diane E. Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | SOBECKI CHRISTOPHER J Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | Cheung Ivan Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | BARKER SAM L Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | Amouyal Philippe Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | DEBBANE RAYMOND Director | Option | 89,312 | — | Form 4 |
| Apr 30, 2026 | Artal Participations S.a r.l. Director | Option | 20,421,735 | — | Form 4 |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option | 144,393 | — | Form 4 |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Other | 68,107 | $100K | Form 4 |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option | 52,316 | — | Form 4 |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option | 27,697 | — | Form 4 |
| Feb 28, 2026 | Martens Rachel Yap SVP, Partnerships & Corp Strat | Option | 67,090 | — | Form 4 |
| Feb 28, 2026 | Martens Rachel Yap SVP, Partnerships & Corp Strat | Other | 35,826 | $53K | Form 4 |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option | 202,260 | — | Form 4 |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Other | 109,098 | $160K | Form 4 |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option | 74,226 | — | Form 4 |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option | 35,790 | — | Form 4 |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option | 65,640 | — | Form 4 |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Other | 24,338 | $36K | Form 4 |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option | 20,310 | — | Form 4 |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option | 14,000 | — | Form 4 |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Option | 128,190 | — | Form 4 |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Other | 74,572 | $110K | Form 4 |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Option | 24,674 | — | Form 4 |
Martens Rachel Yap
SVP, Partnerships & Corp Strat
日期
Feb 28
股数
35,826
均价
$1.47
总金额
$53K
Granowitz Craig B
SVP, Chief Medical Officer
日期
Feb 28
股数
109,098
均价
$1.47
总金额
$160K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 LXRX 内幕交易
LXRX 内幕交易
Lexicon Pharmaceuticals, Inc.（LXRX）内幕交易数据来源于公司内部人（包括DEBBANE RAYMOND (Director), McDermott Wendy (SVP, Human Resources), Granowitz Craig B (SVP, Chief Medical Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。LXRX内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Lexicon Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
LXRX 内幕交易 · 5个问题Lexicon Pharmaceuticals, Inc.（LXRX）的内部人包括高管和董事，如DEBBANE RAYMOND (Director), McDermott Wendy (SVP, Human Resources), Granowitz Craig B (SVP, Chief Medical Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026